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A B S T R A C T
Azathioprine (AZA), an oral immunosuppressant, is safe during pregnancy. Some reports suggested different
impairments in the offspring of mothers with autoimmune diseases (AI) exposed in utero to AZA. These ob-
servations are available from retrospective studies or case reports. However, data with respect to the long-term
safety in the antenatally exposed child are still lacking. The aim of this study is to summarize the current
knowledge in this field and to focus on the need for a prospective study on this population. We performed a
PubMed search using several search terms.
The actual data show that although the risk of congenital anomalies in offspring, as well as the infertility risk,
are similar to those found in general population, there is a higher incidence of prematurity, of lower weight at
birth and an intra-uterine delay of development. There is also an increased risk of materno- fetal infections,
especially cytomegalovirus infection. Some authors raise the interrogations about neurocognitive impairment.
Even though the adverse outcomes might well be a consequence of maternal illness and disease activity, interest
has been raised about a contribution of this drug. However, the interferences between the external agent (in
utero exposure to AZA), with the host (child genetic susceptibility, immune system anomalies, emotional status),
environment (public health, social context, availability of health care), economic, social, and behavioral con-
ditions, cultural patterns, are complex and represent confounding factors.
In conclusion, it is necessary to perform studies on the medium and long-term outcome of children born by
mothers with autoimmune diseases, treated with AZA, in order to show the safety of AZA exposure. Only large-
scale population studies with long-term follow-up will allow to formally conclude in this field.
Take home messages:
• There is no study on a significant number of subjects concerning the medium and long-term outcome of
children born by mothers with autoimmune disease treated with AZA.• As AZA use is related to underlying disease and disease activity and many confounders interfere with AZA
treatment, there is a major difficulty to distinguish between the influence of the disease itself on the risk of
adverse birth outcome and potential AZA effects in offspring at medium and long term.• Data need to be implemented with large, multicenter studies.
1. Introduction
Although autoimmune diseases (AI) are rare, their prevalence as
whole group of diseases is estimated to be around 9.4% in the general
population [1].
Beside a large variety of immunosuppressive drugs and biotherapies
currently used, several new therapies emerge at now [2–4].
Nevertheless, several unmeet need still remain in rheumatology and
autoimmune disease [5].
The activity of disease in pregnant women with autoimmune dis-
eases requires sometimes the use of immunosuppressive drugs, among
which Azathioprine (AZA) is one of the best studied and widely pre-
scribed. Although AZA is considered safe during pregnancy [6–8], some
reports suggested different impairments in the offspring of mothers
with AI exposed to AZA. The complications reported in these children
mainly consisted in congenital malformations, preterm birth and low
birth weight, neurocognitive problems, temporary immunological dis-
turbances. These observations are mostly derived from retrospective
studies (cohorts with no control groups) or case reports, therefore the
quality of evidence of the relationship with antenatal exposure to AZA
is low. Data with respect to the long-term safety in the antenatally
exposed child are still lacking.
Prematurity and intrauterine growth restriction (IUGR) and some
reversible hematological anomalies have been reported in children
exposed to AZA, but maternal disease activity during pregnancy could
be a confounder. In addition, some authors reported a lower birth
weight and a higher rate of prematurity [9], impaired neonatal hema-
topoiesis [10], atrial or ventricular septal defects [11] after AZA in
utero exposure. A maternal-fetal infectious risk (particularly to CMV)
could be possibly related to the immunosuppression induced by AZA.
There are limited and controversial data on the long-term neuro-
development of children exposed in utero to AZA [12,13]. Most of the
data regarding the use of AZA during pregnancy derive from non-sys-
temic lupus erythematosus (SLE), non-systemic autoimmune diseases
cohorts, but rather from renal transplantation. Some data are available
from inflammatory bowel diseases (IBD) patients. There are also reports
on neurocognitive impairment (autism, learning disabilities and special
educational services) as related to AZA antenatal exposure in auto-
immune diseases [14,15].
This review summarizes the current knowledge in the field of health
of children exposed to AZA born to mothers with various AI and par-
ticularly with SLE and strengthens the need for a prospective study on
this population.
We performed a PubMed search using the search terms azathioprine
AND in utero exposure, azathioprine AND birth outcome, azathioprine AND
Intrauterine exposure, immunosuppressive therapy AND pregnancy, anti-
rheumatic drugs AND pregnancy, azathioprine AND foetus, azathioprine
AND paternal exposure, offspring and azathioprine, azathioprine AND in-
fertility, fetal toxicity AND immunosuppressive drugs in pregnancy, aza-
thioprine AND expectant fathers, azathioprine AND breast feeding, mer-
captopurine AND birth outcome, thiopurine AND pregnancy, azathioprine
AND inflammatory bowel disease, azathioprine AND Systemic lupus er-
ythematosus, azathioprine AND Transplant, azathioprine AND Crohn's
disease, azathioprine AND ulcerative colitis, azathioprine AND autoimmune
disease, mercaptopurine AND inflammatory bowel disease, mercaptopurine
AND Systemic lupus erythematosus, mercaptopurine AND Transplant,
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mercaptopurine AND Crohn's disease, mercaptopurine AND ulcerative co-
litis, mercaptopurine AND autoimmune disease.
References from selected papers were reviewed and used if relevant.
2. Pharmacological properties of AZA
Azathioprine is an antimetabolite which is 80% metabolized to 6-
mercaptopurine (6-MP). 6-MP, in turn, is changed into the active me-
tabolite 6-thioguaninenucleotide (6-TGN). Approximately 47% of orally
given AZA is absorbed, whereas 6-MP is, on average, only 16% ab-
sorbed. A teratogenic potential in humans has not been identified. It
may be prescribed during pregnancy. The placental transfer is limited
[16]; however, 6-TGN was found in similar concentrations in the ery-
throcytes of three mothers and their healthy newborns [17]. Jharap
et al. discussed whether the maternally derived metabolites, and not the
maternal drug, crossed the placental barrier [18]. They prospectively
analyzed thiopurine metabolism before, during, and after pregnancy in
30 mother-child pairs (31 infants) and found that during pregnancy,
maternal 6-TGN decreased, white 6-methylmercaptopurine (6-MMP)
increased [18].
The enzyme inosinatopyrophosphorylase is lacking in the fetal liver,
and, as it converts AZA to its active form, the fetus should therefore be
theoretically protected from AZA crossing the placenta [19,20].
3. Use of AZA during pregnancy: data on teratogenicity
AZA has been shown to induce teratogenic effects (limb, eye, digits,
skeletal, CNS) in various animals (rat, mouse, rabbit, and hamster)
[21].
There are no conclusive cases of human malformations attributed to
maternal treatment with AZA.
U.S. Food and Drug Administration's (FDA) pregnancy category
places AZA in category D (for all Trimesters): there is positive evidence
of human fetal risk, but the benefits from use in pregnant women may
be acceptable despite the risk (e.g., if the drug is needed in a life-
threatening situation or for a serious disease for which safer drugs
cannot be used or are ineffective).
Also, the Australian TGA Drug Evaluation Committee's category
places AZA in category D drugs which have caused, are suspected to
have caused, or may be expected to cause an increased incidence of
human fetal malformations or irreversible damage. These drugs may
also have adverse pharmacological effects.
CRAT (French Teratogenic Agents Reference Center) advices to not
discontinue treatment if AZA is necessary for the mothers' health during
the preconception period and pregnancy, as data with respect to po-
tential malformations are reassuring.
According to CRAT, on few small-sized clinical series in which
children exposed in utero to AZA were followed-up until 18th years old
showed reassuring data; only one case of hepatoblastoma was reported.
Most of the reports with respect to AZA come from the National
Transplantation Pregnancy Registry (NTPR) in the United States related
to immunosuppressive medication and pregnancy, although the authors
estimate that all of the registry data combined only represents one-third
of the available information [22–24].
Some authors analyzed the pregnancy outcomes in female renal
transplant recipients with SLE versus those with other diagnoses [25].
Overall, children's health was reported to be good, prematurity and low
birthweight were found in both groups and there were no apparent
malformations [25]. They found that outcomes were comparable to
renal recipients with other diagnoses.
There are also some reports in AI, but consistent data are mostly
available in IBD. Anecdotal experience has associated prenatal exposure
to AZA with different congenital anomalies, but none of them were
clearly linked to the drug. Other reported events after antenatal ex-
posure to AZA were transient chromosomal anomalies in clinically
normal infants [26].Ta
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Rajapakse et al. reported a higher incidence of spontaneous abor-
tions and congenital malformations in children with fathers treated
with 6-MP for IBD at conception or in the previous 3 months as com-
pared with a control group [27]. Nevertheless, the overall rate of
congenital malformations was similar with the rate observed in the
general populations of newborns.
Subsequently, these data were not confirmed by other groups [28].
All these data are summarized in Table 1.
4. In utero exposure to AZA: are there any consequences on birth
weight and gestational age at delivery?
Consistent data with respect to birth weight and term birth originate
mostly from registries of renal transplant patients [22–25,30–33].
In most of the series of children from one of parents with renal
transplants, which were prenatally exposed to AZA, premature birth
and lower weight at birth were reported [22–25,30–33].
There are further information available in AI, particularly in IBD
and SLE.
The observations on offspring of parents with IBD are controversial,
as some authors reported higher rates of prematurity and lower birth
weight [9,35,36,42], data not confirmed by others [28,38,43,45,46]
(Table 2).
5. Use of AZA during lactation
Azathioprine and its metabolites were found in breast milk, ex-
posing the child to 0.1% of the maternal dose [47].
World Health Organization Rating advices to avoid breastfeeding
during the intake of AZA.
Breastfeeding while treated with AZA is not recommended by the
manufacturer [48]. Therefore, related to the tumorigenic potential of
azathioprine, the manufacturer advice to discontinue nursing or dis-
continue the drug.
Low concentrations of AZA and its metabolites are found in breast
milk [49]. In a prospective observational study low 6-mercaptopurine
(MP-6 levels) were detected in 2 of 31 breast milk samples (n = 10),
and the absence of detectable infant serum MP-6 or 6 thioguanine nu-
cleotide (6-TGN) levels leaded the authors to suggest that AZA-treated
women with normal thiopurine methyltransferase activity may breast-
feed [50]. Another prospective study in 8 children extrapolated a
maximum infant exposure of less than 0.008 mg 6-MP/kg/body
weight/day (Iess than 1% of the maternal dose) [51].
Two other cases were reported by Moretti ME et al. who suggested a
negligible infant exposure, with no adverse events in infant's breastfed
by mothers receiving AZA [52].
Recently, it has been reported that breastfeeding does not expose
the newborn to an increased risk of infections [53]. Nevertheless, lack
of evidence and/or expert consensus lead to the recommendation for
determining infant risk when used during breastfeeding. A balance
between potential benefits of drug treatment against potential risks
should be addressed before prescribing this drug during breastfeeding.
6. Fertility
Overall reports converge to the conclusion that AZA does not in-
fluence the fertility of women. In men treated with AZA, Dejaco et al.
reported normal semen quality and quantity despite long-term treat-
ment exposure [54].
7. In utero exposure to AZA and fetal morbidity and mortality
IUGR has been reported in fetuses of renal graft mothers treated
with corticosteroids and AZA) (52% vs. 17%, P = .001) [33,55].
A higher rate of hospitalization in neonatal intensive care unit (35%
vs. 6%, P = .01) [33], perinatal mortality (OR 20, 95%CI 2.5–161.4) Ta
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[32], and stillbirth [32] have been also observed in offspring of renal
transplant patients exposed to AZA.
Cytomegalovirus infection [29–31,56], and observations of jaun-
dice, respiratory distress syndrome [29], diabetes mellitus, asthma [32]
were anecdotally reported.
These data are summarized in Table 3.
8. Immunological impairment
Immunological impairment was also observed; in most of the cases
such as transient lymphopenia and depressed hematopoiesis
[10,26,29–31,44,56–58].
Two cases of severe immune deficiency [56,58] in children from
renal transplant recipients and another case of autoimmunity in a child
from SLE mother [59] were also reported.
Postnatal enhancement of T cell maturation, but otherwise normal
immunological development was reported in one case [60].
In the offspring of parents with various AI the response to vacci-
nation with C. Tetani toxoid was tested and 17% of the children did not
achieve a protective titer of anti C. Tetani toxoid IgG [61].
Nevertheless, no immunological impairment has been reported in
this population [61–63].
The findings on immunological impairment of children are sum-
marized in Table 4.
9. Outcome of children born to mothers with systemic lupus
erythematosus. Is there any evidence of long-term effect of AZA
exposure during intrauterine life?
There is consensus in international groups on the use of AZA during
pregnancy. In 2007, the European League Against Rheumatism
(EULAR) released recommendations for the treatment of SLE [65].
International groups have been working on the use of anti-rheu-
matic drugs during pregnancy [6,8,66–69].
The 2017 EULAR actualized these recommendations on pregnancy,
in which it is clearly stated that AZA is a drug to be considered for the
maintenance of SLE remission during pregnancy [6].
Several factors possibly interfering with the intrauterine life were
suggested to posses a major role in the global development of the
children:
1) Maternal disease activity [70–74].
2) SLE autoantibodies such as anti-Ro/SSA antibodies [70]: antipho-
spholipid antibodies (aPL) [75–78].
3) Anti-rheumatic drugs [14,15,73,74].
These factors could have some potential consequences on children,
such as intrauterine growth retardation (IUGR) and prematurity
[70,71]. In the postnatal life, three patterns of outcomes have been
particularly studied in children born to mothers with SLE:
a) Infectious diseases
b) Neurocognitive impairement
c) Immunological abnormalities
These different potential factors responsible for the occurrence of a
developmental impairment, as well as the potential consequences of
these factors are summarized in the Fig. 1.
Several studies highlighted gestational complications and impaired
developmental outcome related to the activity of disease during preg-
nancy [70–74]. The studies of Neri et al. [71] and of Ross et al. [70]
showed not only a risk of prematurity, a low weight at birth and the
intra-uterine delay of development, but also learning difficulties, to be
directly correlated with disease activity of the pregnant women.
Fig. 1. Potential impairing factors and their potential consequences in child development.
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Neurocognitive impairment (NI) has been described in preschool-
age children of SLE mothers and it has been suggested that it would be
related to different factors. However, the pathogenic mechanisms are
unknown. Ross et al. reported that SLE in pregnant women is associated
with an increased risk for learning impairment in children, particularly
in male offspring, and suggested as being related to maternal antibodies
(ab) anti-Ro [70]. NI in children has been considered as potentially
related to maternal disease or prematurity [72–74], and/or aPL
[75–78], and/or treatment of mothers [73,74].
Although immunosuppressants such as AZA are considered safe
during pregnancy [6–8], some data report immune anomalies and NI
(autism, learning disabilities and special educational services) as re-
lated to AZA antenatal exposure [14,15] in SLE. Maternal SLE is sig-
nificantly associated with attention disorders after multivariate analysis
including treatment during pregnancy in some studies [79,80].
The consequences of AZA utilization in the respective fathers is also
a matter a debate, but nowadays data are available only from non-SLE
cohorts [27,81].
In utero AZA exposure was found to be associated with increased
utilization of special educational services [14], but breast-feeding does
not expose the newborn to infectious risks [53]. However, series are
very small, retrospective, not homogenous and no formal conclusion
could be drawn. The larger retrospective series [15] showed a risk of
autism disorders in SLE offspring but missed to explore all the different
items of the children outcome (neuro-cognitive development, height
and weight development, immunity, infectious risk). Also, in this ret-
rospective study only in 7 children AZA exposure could be identified.
These data are summarized in Table 5.
However, these data remain controversial.
10. Discussion
Although Azathioprine is an “old” immunosuppressive therapy, re-
cent data are available.
Therefore, new mechanisms and effects have been reported [83,84].
Recently, it has been shown that azathioprine increases BAFF levels in
systemic lupus erythematosus [83]. Morover, although an increased
risk of cervical HPV infection in women with SLE compared to healthy
controls was found, AZA treatment is not associated with the risk of
cervical infection in SLE women [84].
This drug still raises interrogations.
Nowadays, it is not known if the reported impairments described in
offspring from parents treated with AZA are exclusively related to the
exposure to AZA, or if several complementary factors act as con-
founding factors such as the contribution of the maternal/paternal
disease, the immune anomalies, the socio-economic and environmental
exposure; and also if a particular category of children are particularly
predisposed to develop these disabilities.
Therefore, a recent meta-analysis of 24 cohort and 4 case-control
studies identified learning disorders (LD) in 21.4–26% of SLE offspring,
exceeding the prevalence in the general population [85]. In lupus off-
spring compared to controls a twofold increased rate of autism spec-
trum disorders (ASD) in one study and a two- to threefold increased risk
for speech disorders in 3 studies were reported [85]. In four studies of
this meta-analysis dyslexia and reading problems have been reported in
14.3–21.6% of lupus offspring with a clear male predominance [81].
Some divergent results were found for attention deficit and behavior
disorders; and notably IQ and motor skills were not affected in re-
spectively 7 and 5 studies [85].
Data with respect to the occurrence of immune abnormalities in SLE
offspring are controversial [61–63]. Temporary immunological and NI
in children from SLE mothers were reported at birth [42,57]. Therefore,
it is important to search for a potential impairment of the immune
system in children from SLE parents with or without AZA treatment
after the age of 24 months; age when their immune system is devel-
oped. The role of immune abnormalities related to parental immune
background with further consequences of the NI of the child could be
also suggested.
In the recent meta-analysis of 28 studies by Yousef Yengej et al. the
positivity of maternal anti-Ro/SSA antibodies was associated with
learning disorders in the offspring in one study [85]. No formal con-
clusions could be drawn with respect to the other SLE-related anti-
bodies and neurocognitive outcome of children as they were only very
rarely studied [85].
As literature objectified correlations between the nervous and im-
mune systems development, and as immune anomalies were described
in neurocognitive disease [86,87], it is essential to identify the potential
impairment of the immune system in children from SLE mothers in
whom mental health impairment will be detected.
Nowadays, all these data are controversial, as well as the respon-
sibility of the SLE activity itself, the concomitant presence of different
antibodies such as aPL, other antibodies in mothers (anti-Ro/SSA, anti-
La/SSB), and/or the direct deleterious effects of drugs.
Besides these risk factors, prematurity, genetics, environmental and
socioeconomic factors, as well as sex determinants [70]; societal, cul-
tural, lifestyle, epidemiological, economic and environmental factors
could be responsible for the global developmental outcome and parti-
cularly neurocognitive and immunological outcome of these children.
Moreover, children are a part of families, of the society, so there is a
need to assure their wellbeing and to be understood holistically. The
interferences between the external agent (in utero exposure to AZA),
with the host (child genetic susceptibility, immune system anomalies,
emotional status), environment (public health, social context, avail-
ability of health care), economic, social, and behavioral conditions,
cultural patterns, are complex and the need to conclude on their po-
tential participation to the well-being of this population is mandatory.
As related to maternal background, several genetic, geoepidemiologic,
but also socio-economic and cultural factors, could display an impact on
the results of such studies, we consider that it is essential to state on the
safety of AZA in offspring from AID mothers, both at birth, but also at
medium term, i.e. at least 3 years of age, representing the minimal
period required to evaluate the neurocognitive potential and the social
integration in the preschool life.
11. Conclusion
AZA, an immunospressive used in patients with a large diversity of
autoimmune disease and transplantation [3,4,25,26,28,31,34–36,
38,39,45,88–93], is generally the immunosuppressive of choice in high-
risk pregnancy because of the safety profile and its steroid-sparing
property [6–8].
As AZA use is related to underlying disease and disease activity,
there is a major difficulty to distinguish between the influence of the
disease itself on the risk of adverse birth outcome and potential AZA
effects. Another major problem complicating the interpretation of data
is the confusion by different indications.
Many confounders interfere with AZA treatment like indication for
treatment and concomitant medication. Patients with autoimmune
disease and especially transplant recipients usually do not receive
monotherapy, and therefore adverse outcomes in this group could re-
late to the underlying disease as well as concomitant medications,
several of them powerful immunomodulators.
The adverse pregnancy outcomes described in older studies were an
increased rate of spontaneous miscarriage, preterm delivery and low
birthweight, which could have been caused by the underlying disease
rather than by the use of thiopurines. More recent controlled studies,
such as for instance, in IBD, reported no increased risk for adverse
pregnancy outcome in IBD patients treated during pregnancy with
thiopurines, compared with pregnancy outcomes of IBD patients
without this treatment [94,95].
Nevertheless, nowadays, there is no study on a significant number of
subjects concerning the medium and long-term outcome of children
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born by autoimmune disease mothers, and particularly SLE mothers,
treated with AZA and, consecutively, the necessity of such a study to
show the safety of AZA exposure is mandatory. Even though the adverse
outcomes might well be a consequence of maternal illness and disease
activity, interest has been raised about this drug and data need to be
implemented with large, multicenter studies.
Only large-scale population with long-term follow-up, and taking
into account several variables such as maternal background, immune
system anomalies, genetic, geoepidemiologic, socio-economic and cul-
tural factors would allow formal conclusions in this field.
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